ERAS
Price
$10.59
Change
+$8.14 (+332.24%)
Updated
Feb 3 closing price
Capitalization
3.28B
43 days until earnings call
Intraday BUY SELL Signals
IDYA
Price
$34.23
Change
+$7.44 (+27.77%)
Updated
Feb 3 closing price
Capitalization
3B
55 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ERAS vs IDYA

Header iconERAS vs IDYA Comparison
Open Charts ERAS vs IDYABanner chart's image
Erasca
Price$10.59
Change+$8.14 (+332.24%)
Volume$5.67M
Capitalization3.28B
IDEAYA Biosciences
Price$34.23
Change+$7.44 (+27.77%)
Volume$639.01K
Capitalization3B
ERAS vs IDYA Comparison Chart in %
ERAS
Daily Signal:
Gain/Loss:
IDYA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ERAS vs. IDYA commentary
Feb 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and IDYA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 04, 2026
Stock price -- (ERAS: $10.59 vs. IDYA: $34.23)
Brand notoriety: ERAS and IDYA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 94% vs. IDYA: 69%
Market capitalization -- ERAS: $3.28B vs. IDYA: $3B
ERAS [@Biotechnology] is valued at $3.28B. IDYA’s [@Biotechnology] market capitalization is $3B. The market cap for tickers in the [@Biotechnology] industry ranges from $118.13B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 0 FA rating(s) are green whileIDYA’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 0 green, 5 red.
  • IDYA’s FA Score: 1 green, 4 red.
According to our system of comparison, IDYA is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 3 TA indicator(s) are bullish while IDYA’s TA Score has 3 bullish TA indicator(s).

  • ERAS’s TA Score: 3 bullish, 5 bearish.
  • IDYA’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than IDYA.

Price Growth

ERAS (@Biotechnology) experienced а +0.81% price change this week, while IDYA (@Biotechnology) price change was -1.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.22%. For the same industry, the average monthly price growth was +3.03%, and the average quarterly price growth was +35.17%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 19, 2026.

IDYA is expected to report earnings on Mar 31, 2026.

Industries' Descriptions

@Biotechnology (-4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($3.28B) has a higher market cap than IDYA($3B). ERAS YTD gains are higher at: 184.543 vs. IDYA (-0.984). ERAS has higher annual earnings (EBITDA): -131.32M vs. IDYA (-204.84M). IDYA has more cash in the bank: 787M vs. ERAS (288M). IDYA has less debt than ERAS: IDYA (27.2M) vs ERAS (48.3M). IDYA has higher revenues than ERAS: IDYA (215M) vs ERAS (0).
ERASIDYAERAS / IDYA
Capitalization3.28B3B109%
EBITDA-131.32M-204.84M64%
Gain YTD184.543-0.984-18,764%
P/E RatioN/AN/A-
Revenue0215M-
Total Cash288M787M37%
Total Debt48.3M27.2M178%
FUNDAMENTALS RATINGS
IDYA: Fundamental Ratings
IDYA
OUTLOOK RATING
1..100
67
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
PROFIT vs RISK RATING
1..100
63
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
45
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASIDYA
RSI
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
64%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
72%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
69%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
86%
Bearish Trend 6 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signal:
Gain/Loss:
IDYA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HFYCX14.600.16
+1.11%
Hartford Schroders Intl Multi-Cp Val C
VMMSX31.080.24
+0.78%
Vanguard Emerg Mkts Sel Stk Inv
BCREX14.990.07
+0.47%
BlackRock Real Estate Securities Inv C
OAYMX171.31-1.50
-0.87%
Oakmark Advisor
ETCEX12.97-0.32
-2.41%
Eventide Exponential Technologies C

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-0.24%
RVMD - ERAS
57%
Loosely correlated
-1.22%
IRON - ERAS
50%
Loosely correlated
-1.17%
IDYA - ERAS
48%
Loosely correlated
+0.50%
ACLX - ERAS
48%
Loosely correlated
-0.01%
NRIX - ERAS
48%
Loosely correlated
-1.76%
More

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+0.50%
NUVL - IDYA
59%
Loosely correlated
+2.12%
OCUL - IDYA
57%
Loosely correlated
-6.99%
XENE - IDYA
56%
Loosely correlated
+1.62%
XNCR - IDYA
55%
Loosely correlated
-0.99%
BEAM - IDYA
54%
Loosely correlated
-0.11%
More